Game Plan Financial Advisors’s BioXcel Therapeutics BTAI Stock Holding History

Game Plan Financial Advisors’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-705	Closed	-$133K	–	90
2022 Q3	$133K	Buy	705 +25	+4%	+$5.8K	0.11%	69
2022 Q2	$142K	Buy	+680	New	+$143K	0.11%	77
2020 Q3	–	Sell	-293	Closed	-$248K	–	54
2020 Q2	$248K	Buy	+293	New	+$191K	0.36%	38
2020 Q1	–	Sell	-781	Closed	-$183K	–	92
2019 Q4	$183K	Buy	+781	New	+$78.5K	0.17%	80

Other funds holding BTAI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BPA

Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return

Game Plan Financial Advisors's BTAI Position: Q4 2022 in Review

Game Plan Financial Advisors sold out of BioXcel Therapeutics (BTAI) in Q4 2022, closing a stake of 705 shares — an estimated $133K sold.

Game Plan Financial Advisors first reported a position in BTAI in Q4 2019 and held it in 4 quarters. The position peaked at $248K in Q2 2020. 83 funds tracked by Wall St. Rank hold BTAI as of Q4 2022.

Game Plan Financial Advisors reported no remaining BioXcel Therapeutics position as of Q4 2022 after selling out during the quarter.
Game Plan Financial Advisors sold 705 BioXcel Therapeutics shares in Q4 2022, an estimated $133K.
Game Plan Financial Advisors first reported a position in BioXcel Therapeutics in Q4 2019 and held it in 4 quarters.
Game Plan Financial Advisors's BioXcel Therapeutics position peaked at $248K in Q2 2020.
83 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2022.

Based on Game Plan Financial Advisors's 13F filing for Q4 2022, filed 10 Feb 2023.